World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
21214
World Ranking
17209
National Ranking
568

François Doz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where François Doz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 362 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

François Doz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where François Doz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

François Doz is affiliated with Université Paris Cité in France and has a significant research presence in the field of medicine. Their work primarily revolves around cancer-related topics, with a focus on genetics, neurology, molecular biology, pulmonary and respiratory medicine, and oncology.

The researcher's publications span a range of main topics including glioma diagnosis and treatment, neuroblastoma research and treatments, childhood cancer survivors' quality of life, ocular oncology and treatments, lung cancer treatments and mutations, brain metastases and treatment, and cancer genomics and diagnostics.

Frequent co-authors collaborating with François Doz include:

  • Birgit Geoerger
  • Franck Bourdeaut
  • Theodore W. Laetsch
  • Christelle Dufour
  • Alexander Drilon

Publishing regularly in a number of prominent venues, François Doz has contributed many papers to:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Pediatric Blood & Cancer
  • European Journal of Cancer

Among the recent papers associated with François Doz are:

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, 2020, The Lancet Oncology
  • Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors, 2021, Neuro-Oncology
  • Failure of human rhombic lip differentiation underlies medulloblastoma formation, 2022, Nature
  • A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression, 2021, Nature Communications
  • The transcriptional landscape of Shh medulloblastoma, 2021, Nature Communications

Best Publications

  • Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

    Marcel Kool;Andrey Korshunov;Marc Remke;Marc Remke;David T.W. Jones

  • Subgroup-specific structural variation across 1,000 medulloblastoma genomes

    Paul A. Northcott;Paul A. Northcott;David J.H. Shih;John Peacock;Livia Garzia

  • Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

    Marcel Kool;David T.W. Jones;Natalie Jäger;Paul A. Northcott

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

    Vijay Ramaswamy;Marc Remke;Eric Bouffet;Simon Bailey

  • Histopathologic risk factors in retinoblastoma: A retrospective study of 172 patients treated in a single institution

    F Khelfaoui;P Validire;A Auperin;E Quintana

  • Cytogenetic Prognostication Within Medulloblastoma Subgroups

    David J.H. Shih;Paul A. Northcott;Marc Remke;Andrey Korshunov

  • Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial

    Birgitta Lannering;Stefan Rutkowski;Francois Doz;Barry Pizer

  • Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology

    Jacques Grill;Marie-Cécile Le Deley;Danièle Gambarelli;Marie-Anne Raquin

  • Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.

    Jean-Sébastien Guillamo;Alain Créange;Chantal Kalifa;Jacques Grill

  • Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children

    Jacques Grill;Christian Sainte-Rose;Anne Jouvet;Jean-Claude Gentet

  • A proposal for an international retinoblastoma staging system

    Guillermo Chantada;François Doz;Celia B.G. Antoneli;Richard Grundy

  • Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.

    Sarah Fattet;Sarah Fattet;Sarah Fattet;Christine Haberler;Christine Haberler;Christine Haberler;Patricia Legoix;Pascale Varlet

  • Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor.

    Franck Bourdeaut;Delphine Lequin;Laurence Brugières;Stéphanie Reynaud

  • Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy—Results of the First French Prospective Study for the French Society of Pediatric Oncology

    Véronique Laithier;Jacques Grill;Marie-Cécile Le Deley;Marie-Madeleine Ruchoux

  • Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma.

    Xavier Sastre;Guillermo L. Chantada;François Doz;Matthew W. Wilson;Matthew W. Wilson

  • Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma

    Sophie Postel-Vinay;Amélie S Véron;Franck Tirode;Gaelle Pierron

  • Temozolomide in Malignant Gliomas of Childhood: A United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

    Linda S Lashford;P Thiesse;A Jouvet;T Jaspan

  • TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

    Marc Remke;Vijaj Ramaswamy;John Peacock;David J.H. Shih

  • High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma : A SFOP and SFGM study

    F Namouni;F Doz;M.L Tanguy;E Quintana

Frequent Co-Authors

Gilles Vassal
Gilles Vassal Institut Gustave Roussy
Jacques Grill
Jacques Grill Institut Gustave Roussy
Olivier Delattre
Olivier Delattre PSL University
Stefan Rutkowski
Stefan Rutkowski Universität Hamburg
Jean Michon
Jean Michon Institute Curie
Eric Bouffet
Eric Bouffet University of Toronto
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center
Claude Houdayer
Claude Houdayer Centre Hospitalier Universitaire de Rouen
Steven C. Clifford
Steven C. Clifford Newcastle University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the field of medicine goes beyond becoming a doctor. There are a variety of online programs that open doors to healthcare careers, many of which offer flexibility for working adults and students with diverse backgrounds.

For example, online BSN programs for non nurses allow those without a prior nursing background to enter this rewarding field through accelerated learning. Similarly, students interested in administrative roles may benefit from a degree in healthcare administration, which prepares graduates for leadership and management positions in health organizations.

Not everyone wants to pursue patient care. If you prefer working behind the scenes, a career in medical coding and billing is a great option. Discover top medical billing and coding online schools that often provide financial aid and certification pathways. Additionally, there are nursing schools that don’t require TEAS or HESI testing, which can streamline the admissions process for aspiring nurses.

Each of these online degrees presents a unique career pathway, expanding options for those interested in healthcare professions within the USA.

Best Scientists Citing François Doz

Trending Scientists

Recently Published Articles